RECRUITING

Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.

Official Title

Tempus Small Cell Lung Cancer Observational Study (Sculptor): a Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays

Quick Facts

Study Start:2022-07-13
Study Completion:2026-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05257551

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Sculptor Study
CONTACT
833-514-4187
sculptor-study@tempus.com

Principal Investigator

Virginia Rhodes, MD
PRINCIPAL_INVESTIGATOR
Tempus AI, Inc.

Study Locations (Sites)

Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720
United States
University of Colorado
Aurora, Colorado, 80045
United States
Illinois Cancer Care
Peoria, Illinois, 61615
United States
Johns Hopkins University
Baltimore, Maryland, 21287
United States
Englewood Health Medical Center
Englewood, New Jersey, 07631
United States
University of North Carolina
Chapel Hill, North Carolina, 27599
United States
TriHealth Cancer Institute
Cincinnati, Ohio, 45220
United States
Ohio State University
Columbus, Ohio, 43210
United States
OhioHealth Research Institute
Columbus, Ohio, 43214
United States
Oklahoma Cancer Specialists and Research Institutes
Tulsa, Oklahoma, 74146
United States
Cancer Care Association of York
York, Pennsylvania, 17403
United States

Collaborators and Investigators

Sponsor: Tempus AI

  • Virginia Rhodes, MD, PRINCIPAL_INVESTIGATOR, Tempus AI, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-13
Study Completion Date2026-03

Study Record Updates

Study Start Date2022-07-13
Study Completion Date2026-03

Terms related to this study

Keywords Provided by Researchers

  • Cancer
  • Oncology
  • Observational
  • Genomic Profiling
  • Precision medicine
  • SCLC
  • Small Cell Lung Cancer
  • NGS
  • Biomarkers
  • ctDNA
  • Transcriptomics

Additional Relevant MeSH Terms

  • Small Cell Lung Cancer